[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650221":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":16,"responsibleParty":30,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":19,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Japanese patients with IPF\u002FPPF",null,[12],{"name":5,"role":13,"phone":14,"phoneExt":10,"email":15},"CONTACT","1-800-243-0127","clintriage.rdg@boehringer-ingelheim.com",[17],{"facility":18,"status":19,"city":20,"state":10,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Nippon Boehringer Ingelheim Co., Ltd.","RECRUITING","Tokyo","141-6017","Japan","JP",{"type":25,"coordinates":26},"Point",[27,28],139.69171,35.6895,{"lat":28,"lon":27},{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100650221","emotional-and-social-experiences-of-antifibrotic-af-therapy-among-idiopathic-pulmonary-fibrosis-ipfprogressive-pulmonary-fibrosis-ppf-patients-a-real-world-study-100650221",false,"NCT07743996","Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)\u002FProgressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study","A Real-World Study of the Perceived Emotional and Social Experiences Related to Antifibrotic Therapy in Patients With IPF and PPF: A Cross-Sectional Web-Based Survey","Inclusion Criteria:\n\n1. Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks\n2. Patients capable of responding to a self-administered questionnaire\n\nExclusion Criteria:\n\n1. Patients treated with nerandomilast (including clinical trials)\n2. Patients with PPF treated with pirfenidone\n3. Patients currently hospitalized\n4. Patients with malignant tumors","ALL","40 Years",{"count":42,"type":43},100,"ESTIMATED","OBSERVATIONAL","This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire.\n\nThis study tries to find out the attitudes toward and experiences of the emotional and\u002For social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)\u002FProgressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.",[47,48],"Idiopathic Pulmonary Fibrosis","Progressive Pulmonary Fibrosis","2026-08-10",{"date":51,"type":52},"2026-08-12","ACTUAL",{"date":54,"type":52},"2026-08-01",{"date":56,"type":43},"2026-09-30",{"name":5,"class":6},1]